Physician profile
Daniel Hulse
NPI 1013654565
$285.70
in general payments reported to CMS, 2019-2025
9 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.74 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $68.41 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.50 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $34.34 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $32.82 | 2025 | Wegovy |
| Abbvie INC. | $30.07 | 2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2025 | Breztri |
| Csl Behring | $16.74 | 2023 | Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $14.00 | 2025 | Trintellix |
| Sumitomo Pharma America, INC. | $13.55 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hulse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.